Clinical Trials Logo

Epidermolysis Bullosa clinical trials

View clinical trials related to Epidermolysis Bullosa.

Filter by:

NCT ID: NCT00881556 Terminated - Clinical trials for Epidermolysis Bullosa

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

RDEB
Start date: August 20, 2009
Phase: Early Phase 1
Study type: Interventional

Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (AlloSCT) from family-related donors and unrelated cord blood (UCB) donors will be safe and well tolerated in selected patients with RDEB. To determine the event-free survival (EFS) and overall survival (OS) following RIC consisting of busulfan/fludarabine/alemtuzumab (BFA) and AlloSCT in selected patients with RDEB.

NCT ID: NCT00587223 Terminated - Clinical trials for Epidermolysis Bullosa Dystrophica

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the use of Apligraf for the treatment of nonhealing wounds in subjects with dystrophic or junctional epidermolysis bullosa. Apligraf will be evaluated for efficacy and safety compared to a conventional nonadherent dressing. A matched-pair design will be used to evaluate Apligraf treatment versus conventional treatment in 68 study pairs.

NCT ID: NCT00533572 Terminated - Clinical trials for Epidermolysis Bullosa Dystrophica

Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer

Start date: August 2007
Phase: N/A
Study type: Observational

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe inherited blistering skin disease caused by absence of type VII collagen. Patients with RDEB develop large, severly painful blisters and open wounds from minor trauma to their skin. In the future, we hope to start a gene transfer study on a specific group of RDEB subjects and we are screening subjects for that potential trial now.

NCT ID: NCT00478244 Terminated - Clinical trials for Epidermolysis Bullosa

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

Start date: April 2007
Phase: N/A
Study type: Interventional

RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the biochemical and structural abnormalities associated with recessive dystrophic epidermolysis bullosa (RDEB) (collagen 7 deficiency). PURPOSE: To determine the safety and effectiveness of stem cell infusion in the treatment of RDEB.

NCT ID: NCT00311766 Terminated - Clinical trials for Epidermolysis Bullosa

A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa

Start date: February 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate a treatment to enhance the healing of acute and chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with Epidermolysis Bullosa (EB), by the known activity of thymosin beta 4 (Tβ4). Funding Source - FDA Office of Orphan Product Development (OOPD).